{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:21:47Z","timestamp":1772828507780,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ctrv.2012.02.006","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T23:30:51Z","timestamp":1331335851000},"page":"1004-1011","source":"Crossref","is-referenced-by-count":10,"title":["A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"38","author":[{"given":"Mindy M.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Goulart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Beth","family":"Devine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.02.006_b0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1073274810017002S03","article-title":"Chronic lymphocytic leukemia: putting new treatment options into perspective","volume":"17","author":"Pinilla-Ibarz","year":"2010","journal-title":"Cancer Control"},{"key":"10.1016\/j.ctrv.2012.02.006_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.11-1-21","article-title":"Chronic lymphocytic leukemia: recent advances in diagnosis and treatment","volume":"11","author":"Abbott","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2012.02.006_b0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ctrv.2006.05.002","article-title":"Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis","volume":"32","author":"Steurer","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2012.02.006_b0020","unstructured":"Rai KR, Keating MJ. Initial treatment of chronic lymphocytic leukemia. UpToDate online 18.3, updated october 1, 2010."},{"key":"10.1016\/j.ctrv.2012.02.006_b0025","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2012.02.006_b0030","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.ctrv.2012.02.006_b0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00019053-200826090-00006","article-title":"Use of indirect and mixed treatment comparisons for technology assessment","volume":"26","author":"Sutton","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ctrv.2012.02.006_b0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2011","journal-title":"Res Syn Meth"},{"key":"10.1016\/j.ctrv.2012.02.006_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ctrv.2012.02.006_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ctrv.2012.02.006_b0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS \u2013 a Bayesian modeling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"key":"10.1016\/j.ctrv.2012.02.006_b0060","series-title":"Bayesian modeling using WinBUGS","author":"Ntzoufras","year":"2009"},{"key":"10.1016\/j.ctrv.2012.02.006_b0065","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.006_b0070","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.006_b0075","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.02.006_b0080","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.006_b0085","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.02.006_b0090","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomize, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.02.006_b0095","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.02.006_b0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/CMAR.S5621","article-title":"Rituximab for the treatment of patients with chronic lymphocytic leukemia","volume":"2","author":"Gentile","year":"2010","journal-title":"Cancer Manage Res"},{"key":"10.1016\/j.ctrv.2012.02.006_b0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11899-010-0074-6","article-title":"Survival advantage in CLL with frontline FCR therapy","volume":"6","author":"O\u2019Brien","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ctrv.2012.02.006_b0110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1198\/000313001317097960","article-title":"On judging the significance of differences by examining the overlap between confidence intervals","volume":"55","author":"Schenker","year":"2001","journal-title":"Am Stat"},{"key":"10.1016\/j.ctrv.2012.02.006_b0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11899-007-0007-1","article-title":"Prognostic factors in chronic lymphocytic leukemia","volume":"2","author":"Kay","year":"2007","journal-title":"Curr Hematol Malig Rep"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2012.02.006_b0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3310\/hta14suppl2\/04","article-title":"The clinical and cost-effectiveness of rituximab for the 1st line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche","volume":"14","author":"Main","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ctrv.2012.02.006_b0125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2012.02.006_b0130","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T04:12:16Z","timestamp":1561435936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0305737212000278"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.02.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}